- TriLink BioTechnologies and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU) to explore collaboration in mRNA vaccine research and development.
- The partnership aims to improve access to mRNA-based vaccines in low- and middle-income countries (LMICs).
TriLink BioTechnologies, a Maravai LifeSciences company, has signed a Memorandum of Understanding with the International Vaccine Institute (IVI) to explore joint initiatives in mRNA vaccine research, development, and equitable distribution. The agreement sets the foundation for discussions on collaborative models, knowledge sharing, and scientific cooperation.
The MOU outlines potential collaboration areas, including the development of mRNA technologies and the promotion of vaccine access in low- and middle-income countries (LMICs). IVI is a non-profit international organisation headquartered in Seoul, Korea, focused on infectious diseases that disproportionately affect LMICs.
“This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries,” said Becky Buzzeo, Chief Commercial Officer of Maravai and TriLink.
TriLink has a track record in mRNA innovation, notably its CleanCap capping technology used in most approved COVID-19 mRNA and saRNA vaccines. In 2024, the company expanded its mRNA-related product line and opened a GMP manufacturing facility in San Diego, California.
IVI, established in 1997 under a UN initiative, has a portfolio of vaccine candidates targeting diseases such as cholera, typhoid, chikungunya, and hepatitis E. The collaboration is expected to support the development and delivery of advanced mRNA vaccines to populations in need.
Stay ahead of trends and best practices
